Tandem Adds Discovery Capacity

Tandem Labs increased its discovery support capacity at its New England facility in Woburn, MA with the acquisition of additional MDS SCIEX API 5000 and 4000 LC/MS/MS systems. The acquisition doubles the facility’s current triple quadrupole LC/MS/MS capacity.

“Tandem Labs acquired these additional instruments to further increase our capacity in the critical New England region,” said Denis C.K. Lin, Ph.D., president and chief executive officer. “These assets will significantly enhance our reach within the drug discovery and development industry, particularly in Massachusetts as well as other Northeast states.”

The New England operation provides non-GLP discovery PK/PD services, metabolite identification and biomarker services. The facility also uses proprietary informatics to help reduce the difficulty, complexity, and the time it takes to develop and launch a drug to market.

DMDiscovery is a drug metabolism technology that increases the productivity of drug metabolite identification and quantification. MarkerScan is a biomarker discovery and screening process that identifies potential biomarkers that can be used to help understand disease, diagnosis, and predictive models as well as drug safety, efficacy, and side-effect profiles.

Tandem Labs has additional facilities in UT that focus on GLP bioanalytical services and discovery support, and in NJ that specialize in GLP-compliant bioanalysis on LC/MS/MS and immunoanalytical platforms.